JP2024156754A5 - - Google Patents

Download PDF

Info

Publication number
JP2024156754A5
JP2024156754A5 JP2024120747A JP2024120747A JP2024156754A5 JP 2024156754 A5 JP2024156754 A5 JP 2024156754A5 JP 2024120747 A JP2024120747 A JP 2024120747A JP 2024120747 A JP2024120747 A JP 2024120747A JP 2024156754 A5 JP2024156754 A5 JP 2024156754A5
Authority
JP
Japan
Prior art keywords
formulation
glp
months
analog
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024120747A
Other languages
English (en)
Japanese (ja)
Other versions
JP7738136B2 (ja
JP2024156754A (ja
Filing date
Publication date
Priority claimed from EP18197755.4A external-priority patent/EP3628683A1/en
Application filed filed Critical
Publication of JP2024156754A publication Critical patent/JP2024156754A/ja
Publication of JP2024156754A5 publication Critical patent/JP2024156754A5/ja
Application granted granted Critical
Publication of JP7738136B2 publication Critical patent/JP7738136B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024120747A 2018-09-28 2024-07-26 グルカゴン様ペプチド-2(glp-2)類似体の製剤 Active JP7738136B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18197755.4 2018-09-28
EP18197755.4A EP3628683A1 (en) 2018-09-28 2018-09-28 Formulations of glucagon-like-peptide-2 (glp-2) analogues
PCT/EP2019/076305 WO2020065064A1 (en) 2018-09-28 2019-09-27 Formulations of glucagon-like-peptide-2 (glp-2) analogues
JP2021517294A JP7566730B2 (ja) 2018-09-28 2019-09-27 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021517294A Division JP7566730B2 (ja) 2018-09-28 2019-09-27 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Publications (3)

Publication Number Publication Date
JP2024156754A JP2024156754A (ja) 2024-11-06
JP2024156754A5 true JP2024156754A5 (https=) 2025-04-03
JP7738136B2 JP7738136B2 (ja) 2025-09-11

Family

ID=63794308

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517294A Active JP7566730B2 (ja) 2018-09-28 2019-09-27 グルカゴン様ペプチド-2(glp-2)類似体の製剤
JP2024120747A Active JP7738136B2 (ja) 2018-09-28 2024-07-26 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021517294A Active JP7566730B2 (ja) 2018-09-28 2019-09-27 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Country Status (14)

Country Link
US (2) US20220265551A1 (https=)
EP (2) EP3628683A1 (https=)
JP (2) JP7566730B2 (https=)
KR (2) KR20260008798A (https=)
CN (3) CN112771073B (https=)
AU (1) AU2019348538B2 (https=)
BR (1) BR112021005858A2 (https=)
CA (1) CA3114330A1 (https=)
CL (1) CL2021000678A1 (https=)
IL (1) IL281362B1 (https=)
MX (2) MX2021003271A (https=)
NZ (1) NZ775113A (https=)
SG (1) SG11202102383VA (https=)
WO (1) WO2020065064A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
MX2022014671A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida de conjugado de glp-2 de accion prolongada.
MX2023006901A (es) * 2020-12-16 2023-06-26 Zealand Pharma As Uso de analogos de glp-2 en pacientes con insuficiencia renal.
RS67423B1 (sr) * 2021-09-10 2025-12-31 Zealand Pharma As Postupak za formulisanje sastava koji sadrže analoge glukagonu sličnog peptida-2 (glp-2)
IL313732A (en) 2021-12-23 2024-08-01 Zealand Pharma As Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
KR20250075601A (ko) 2022-09-30 2025-05-28 질랜드 파마 에이/에스 글루카곤-유사-펩타이드-2(glp-2) 유사체 및 단장 증후군(sbs) 치료를 위한 이의 의학적 용도
US20240415933A1 (en) * 2022-10-03 2024-12-19 Orbicular Pharmaceutical Technologies Private Limited Stable injectable compositions of glp-2 peptide
IL322328A (en) 2023-01-27 2025-09-01 Zealand Pharma As Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS)
TW202535919A (zh) 2023-12-28 2025-09-16 丹麥商西蘭製藥公司 類升糖素肽2(glp-2)類似物之調配物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
EP1231219B1 (en) 1996-04-12 2010-08-25 1149336 Ontario Inc. GLucagon-like peptide-2 analogs
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2020501A (en) 1999-12-08 2001-06-18 1149336 Ontario Inc. Chemotherapy treatment
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ES2336826T3 (es) * 2005-05-03 2010-04-16 Novetide, Ltd. Procedimientos para la produccion de un peptido que presenta una amida c-terminal.
UA95235C2 (en) * 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10,顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CN101573376B (zh) * 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2(glp-2)类似物
CN101668535B (zh) * 2006-12-29 2017-07-28 益普生制药股份有限公司 Glp‑1药物组合物
KR20130115086A (ko) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
FR2994390B1 (fr) * 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
HRP20161703T1 (hr) * 2012-11-20 2017-03-10 Fresenius Kabi Usa, Llc Formulacije kaspofungin acetata
WO2016065181A1 (en) * 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
LT3541366T (lt) * 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai

Similar Documents

Publication Publication Date Title
JP2024156754A5 (https=)
JP7202272B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
CN103442695B (zh) 肠胃外注射用肽药物的稳定制剂
ES2365410T3 (es) Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
RU2467762C2 (ru) Составы паратиреоидного гормона и их применение
CN107249620B (zh) 一种包含glp-1类似物的药物制剂及其制备方法
JP2009506126A5 (https=)
TW200302720A (en) Highly concentrated stable meloxicam solutions for needleless injection
JP2013505270A5 (https=)
CN103893744B (zh) 一种治疗糖尿病的药物制剂及其制备方法
JP2001525371A (ja) Glp−1製剤
JP4708648B2 (ja) レボシメンダンの医薬溶液
CA2358212A1 (en) Formulations for treating disease and methods of using same
RU2009116531A (ru) Способ лечения остеопороза и используемая в нем композиция
JP2002187852A (ja) 生理活性ペプチド含有粉末
JP2022502432A5 (https=)
EP3142686A2 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
JP2022062153A5 (https=)
US20220031612A1 (en) Uricase gel preparation for external use, preparation method therefor and use thereof
JP2021519321A5 (https=)
EP3373953B1 (fr) Composition a action rapide d'insuline comprenant un citrate substitue
JP5212492B2 (ja) 経鼻投与用医薬組成物
JP2023518052A5 (https=)
CN102440957B (zh) 醋酸特利加压素鼻腔喷雾剂及其制备方法
JP2001163776A (ja) 安定化された液剤